Trial Profile

A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia Sourced From the European Union in Postmenopausal Women With Osteoporosis

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 19 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 May 2025 Status changed from not yet recruiting to withdrawn prior to enrolment. (Business decision not to proceed with the study. )
16 Oct 2024 Planned End Date changed from 1 Oct 2026 to 1 Oct 2027.
16 Oct 2024 Planned primary completion date changed from 1 Oct 2026 to 1 Oct 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com